474 related articles for article (PubMed ID: 27943282)
61. Do platinum salts fit all triple negative breast cancers?
Gerratana L; Fanotto V; Pelizzari G; Agostinetto E; Puglisi F
Cancer Treat Rev; 2016 Jul; 48():34-41. PubMed ID: 27343437
[TBL] [Abstract][Full Text] [Related]
62. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.
Geenen JJJ; Linn SC; Beijnen JH; Schellens JHM
Clin Pharmacokinet; 2018 Apr; 57(4):427-437. PubMed ID: 29063517
[TBL] [Abstract][Full Text] [Related]
63. Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment.
Naipal KA; Verkaik NS; Ameziane N; van Deurzen CH; Ter Brugge P; Meijers M; Sieuwerts AM; Martens JW; O'Connor MJ; Vrieling H; Hoeijmakers JH; Jonkers J; Kanaar R; de Winter JP; Vreeswijk MP; Jager A; van Gent DC
Clin Cancer Res; 2014 Sep; 20(18):4816-26. PubMed ID: 24963051
[TBL] [Abstract][Full Text] [Related]
64. Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines.
Teraoka S; Muguruma M; Takano N; Miyahara K; Kawate T; Kaise H; Yamada K; Miyazawa K; Ishikawa T
J Surg Res; 2020 Jun; 250():200-208. PubMed ID: 32092597
[TBL] [Abstract][Full Text] [Related]
65. Emerging PARP inhibitors for treating breast cancer.
Robert M; Patsouris A; Frenel JS; Gourmelon C; Augereau P; Campone M
Expert Opin Emerg Drugs; 2018 Sep; 23(3):211-221. PubMed ID: 30251552
[TBL] [Abstract][Full Text] [Related]
66. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
67. Biological and clinical significance of PARP1 protein expression in breast cancer.
Green AR; Caracappa D; Benhasouna AA; Alshareeda A; Nolan CC; Macmillan RD; Madhusudan S; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Jan; 149(2):353-62. PubMed ID: 25528020
[TBL] [Abstract][Full Text] [Related]
68. Targeting DNA repair in breast cancer.
Paluch-Shimon S; Evron E
Breast; 2019 Oct; 47():33-42. PubMed ID: 31344602
[TBL] [Abstract][Full Text] [Related]
69. Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics.
Rubinstein WS
Fam Cancer; 2008; 7(1):83-9. PubMed ID: 17624601
[TBL] [Abstract][Full Text] [Related]
70. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
Duma N; Gast KC; Choong GM; Leon-Ferre RA; O'Sullivan CC
Curr Oncol Rep; 2018 Jun; 20(8):63. PubMed ID: 29884921
[TBL] [Abstract][Full Text] [Related]
71. Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.
Alli E; Sharma VB; Sunderesakumar P; Ford JM
Cancer Res; 2009 Apr; 69(8):3589-96. PubMed ID: 19351835
[TBL] [Abstract][Full Text] [Related]
72. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
Akashi-Tanaka S; Watanabe C; Takamaru T; Kuwayama T; Ikeda M; Ohyama H; Mori M; Yoshida R; Hashimoto R; Terumasa S; Enokido K; Hirota Y; Okuyama H; Nakamura S
Clin Breast Cancer; 2015 Feb; 15(1):80-5. PubMed ID: 25445419
[TBL] [Abstract][Full Text] [Related]
73. BRCAness: a deeper insight into basal-like breast tumors.
De Summa S; Pinto R; Sambiasi D; Petriella D; Paradiso V; Paradiso A; Tommasi S
Ann Oncol; 2013 Nov; 24 Suppl 8():viii13-viii21. PubMed ID: 24131964
[TBL] [Abstract][Full Text] [Related]
74. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
Konstantinopoulos PA; Spentzos D; Karlan BY; Taniguchi T; Fountzilas E; Francoeur N; Levine DA; Cannistra SA
J Clin Oncol; 2010 Aug; 28(22):3555-61. PubMed ID: 20547991
[TBL] [Abstract][Full Text] [Related]
75. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.
Comen EA; Robson M
Cancer J; 2010; 16(1):48-52. PubMed ID: 20164690
[TBL] [Abstract][Full Text] [Related]
76. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
[TBL] [Abstract][Full Text] [Related]
77. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
78. p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors.
Cañedo EC; Totten S; Ahn R; Savage P; MacNeil D; Hudson J; Autexier C; Deblois G; Park M; Witcher M; Ursini-Siegel J
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33470989
[TBL] [Abstract][Full Text] [Related]
79. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
80. BRCAness: finding the Achilles heel in ovarian cancer.
Rigakos G; Razis E
Oncologist; 2012; 17(7):956-62. PubMed ID: 22673632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
